CoChat
Sign Up
Cited by 633Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis

Open access
Booth, Heather D.E., Hirst, Warren D., Wade-Martins, Richard·2017·Trends in Neurosciences
DOI 10.1016/j.tins.2017.04.001PMC PMC5462417
Open this paper in CoChat — free accountOpen PDF

Abstract

Astrocytes are the most populous glial subtype and are critical for brain function. Despite this, historically there have been few studies into the role that they may have in neurodegenerative diseases, such as Parkinson's disease (PD). Recently, however, several studies have determined that genes known to have a causative role in the development of PD are expressed in astrocytes and have important roles in astrocyte function. Here, we review these recent developments and discuss their impact on our understanding of the pathophysiology of PD, and the implications that this might have for its treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tins.2017.04.001

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 85

  1. [1]Verkhratsky A. Neurological diseases as primary gliopathies: a reassessment of neurocentrism ASN Neuro 4 2012 e00082 22339481 PMC3320215
  2. [3]Kordower J.H. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease Brain 136 2013 2419 2431 23884810 PMC3722357
  3. [4]Miklossy J. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys Exp. Neurol. 197 2006 275 283 16336966
  4. [7]Lin L.F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 1993 1130 1132 8493557
  5. [8]Schaar D.G. Regional and cell-specific expression of GDNF in rat brain Exp. Neurol. 124 1993 368 371 8287932
  6. [11]Zhang Y. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse Neuron 89 2016 37 53 26687838 PMC4707064
  7. [12]Bandopadhyay R. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease Brain 127 2004 420 430 14662519
  8. [13]Neumann M. Pathological properties of the Parkinson’s disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick’s disease Acta Neuropathol. 107 2004 489 496 14991385
  9. [14]Kim K.S. DJ-1 associates with lipid rafts by palmitoylation and regulates lipid rafts-dependent endocytosis in astrocytes Hum. Mol. Genet. 22 2013 4805 4817 23847046
  10. [15]Kim J.M. DJ-1 deficiency impairs glutamate uptake into astrocytes via the regulation of flotillin-1 and caveolin-1 expression Sci Rep. 6 2016 28823 27346864 PMC4922019
  11. [16]Simons K. Ehehalt R. Cholesterol, lipid rafts, and disease J. Clin. Invest. 110 2002 597 603 12208858 PMC151114
  12. [17]Sillence D.J. New insights into glycosphingolipid functions—storage, lipid rafts, and translocators Int. Rev. Cytol. 262 2007 151 189 17631188
  13. [18]Butchbach M.E. Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function J. Biol. Chem. 279 2004 34388 34396 15187084
  14. [19]Roberts P.J. Davies S.W. Excitatory receptors and their role in excitotoxicity Biochem. Soc. Trans. 15 1987 218 219 2884151
  15. [20]Waak J. Regulation of astrocyte inflammatory responses by the Parkinson’s disease-associated gene DJ-1 FASEB J. 23 2009 2478 2489 19276172
  16. [21]Ashley A.K. DJ-1 mutation decreases astroglial release of inflammatory mediators Neurotoxicology 52 2016 198 203 26691871
  17. [23]Mullett S.J. Hinkle D.A. DJ-1 knock-down in astrocytes impairs astrocyte-mediated neuroprotection against rotenone Neurobiol. Dis. 33 2009 28 36 18930142 PMC2638760
  18. [24]Lev N. Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity J. Mol. Neurosci. 50 2013 542 550 23536331
  19. [25]Mullett S.J. Hinkle D.A. DJ-1 deficiency in astrocytes selectively enhances mitochondrial Complex I inhibitor-induced neurotoxicity J. Neurochem. 117 2011 375 387 21219333 PMC3076514
  20. [26]Mullett S.J. DJ-1 expression modulates astrocyte-mediated protection against neuronal oxidative stress J. Mol. Neurosci. 49 2013 507 511 23065353 PMC3567237
  21. [27]Larsen N.J. DJ-1 knock-down impairs astrocyte mitochondrial function Neuroscience 196 2011 251 264 21907265 PMC3490195
  22. [28]Solano S.M. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson’s disease Ann. Neurol. 47 2000 201 210 10665491
  23. [30]Moore S.A. Astrocytes, not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid (20:4 omega-6) J. Neurochem. 56 1991 518 524 1824862
  24. [31]Castagnet P.I. Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice J. Neurochem. 94 2005 839 849 16033426
  25. [32]Braak H. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson’s disease Acta Neuropathol. 114 2007 231 241 17576580
  26. [33]Hishikawa N. Widespread occurrence of argyrophilic glial inclusions in Parkinson’s disease Neuropathol. Appl. Neurobiol. 27 2001 362 372 11679088
  27. [34]Wakabayashi K. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains Acta Neuropathol. 99 2000 14 20 10651022
  28. [35]Braidy N. Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts Transl. Neurodegener. 2 2013 20 24093918 PMC3853407
  29. [36]Lee H.J. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies J. Biol. Chem. 285 2010 9262 9272 20071342 PMC2838344
  30. [39]Klegeris A. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells FASEB J. 20 2006 2000 2008 17012252
  31. [40]Gu X.L. Astrocytic expression of Parkinson’s disease-related A53T alpha-synuclein causes neurodegeneration in mice Mol. Brain 3 2010 12 20409326 PMC2873589
  32. [41]Gui Y.X. Four novel rare mutations of PLA2G6 in Chinese population with Parkinson’s disease Parkinsonism Relat. Disord. 19 2013 21 26 23182313
  33. [42]Xu J. Oxidant-mediated AA release from astrocytes involves cPLA(2) and iPLA(2) Free Radic. Biol. Med. 34 2003 1531 1543 12788473
  34. [43]Strokin M. Severe disturbance in the Ca2+ signaling in astrocytes from mouse models of human infantile neuroaxonal dystrophy with mutated Pla2g6 Hum. Mol. Genet. 21 2012 2807 2814 22442204 PMC3363330
  35. [44]Strokin M. Proinflammatory treatment of astrocytes with lipopolysaccharide results in augmented Ca2+ signaling through increased expression of via phospholipase A2 (iPLA2) Am. J. Physiol. Cell Physiol. 300 2011 C542 C549 21178110
  36. [45]Arcuino G. Intercellular calcium signaling mediated by point-source burst release of ATP Proc. Natl. Acad. Sci. U. S. A. 99 2002 9840 9845 12097649 PMC125036
  37. [46]Park J.S. The role of ATP13A2 in Parkinson’s disease: clinical phenotypes and molecular mechanisms Mov. Disord. 30 2015 770 779 25900096
  38. [47]Rinaldi D.E. The Parkinson-associated human P5B-ATPase ATP13A2 protects against the iron-induced cytotoxicity Biochim. Biophys. Acta 1848 2015 1646 1655 25912790
  39. [48]Ramirez A. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase Nat. Genet. 38 2006 1184 1191 16964263
  40. [49]Qiao C. Atp13a2 deficiency aggravates astrocyte-mediated neuroinflammation via NLRP3 inflammasome activation CNS Neurosci. Ther. 22 2016 451 460 26848562 PMC6492810
  41. [50]Paisan-Ruiz C. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease Neuron 44 2004 595 600 15541308
  42. [51]Zimprich A. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology Neuron 44 2004 601 607 15541309
  43. [52]Trinh J. Comparative study of Parkinson’s disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism Neurobiol. Aging 35 2014 1125 1131 24355527
  44. [53]Sharma S. LRRK2 expression in idiopathic and G2019S positive Parkinson’s disease subjects: a morphological and quantitative study Neuropathol. Appl. Neurobiol. 37 2011 777 790 21696411
  45. [54]Miklossy J. LRRK2 expression in normal and pathologic human brain and in human cell lines J. Neuropathol. Exp. Neurol. 65 2006 953 963 17021400 PMC7185781
  46. [55]Manzoni C. Inhibition of LRRK2 kinase activity stimulates macroautophagy Biochim. Biophys. Acta 1833 2013 2900 2910 23916833 PMC3898616
  47. [57]Lwin A. Glucocerebrosidase mutations in subjects with parkinsonism Mol. Genet. Metab. 81 2004 70 73 14728994
  48. [58]Stone D.L. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease Hum. Mutat. 15 2000 181 188 10649495
  49. [59]Di Malta C. Astrocyte dysfunction triggers neurodegeneration in a lysosomal storage disorder Proc. Natl. Acad. Sci. U. S. A. 109 2012 E2334 E2342 22826245 PMC3435187
  50. [60]Pontikis C.C. Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation Brain Res. 1023 2004 231 242 15374749
  51. [61]Vitner E.B. Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses Hum. Mol. Genet. 19 2010 3583 3590 20616152
  52. [63]Koyano F. Matsuda N. Molecular mechanisms underlying PINK1 and Parkin catalyzed ubiquitylation of substrates on damaged mitochondria Biochim. Biophys. Acta 1853 2015 2791 2796 25700839
  53. [64]Choi I. PINK1 expression increases during brain development and stem cell differentiation, and affects the development of GFAP-positive astrocytes Mol. Brain 9 2016 5 26746235 PMC4706723
  54. [65]Choi I. PINK1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced AKT and increased p38 MAPK activation, and downregulation of EGFR Glia 61 2013 800 812 23440919 PMC3657120
  55. [66]Kawajiri S. Genetic mutations and functions of PINK1 Trends Pharmacol. Sci. 32 2011 573 580 21784538
  56. [67]Hayashi S. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene Mov. Disord. 15 2000 884 888 11009195
  57. [68]Ishikawa A. Takahashi H. Clinical and neuropathological aspects of autosomal recessive juvenile parkinsonism J. Neurol. 245 1998 P4–9 9808334
  58. [69]Solano R.M. Glial dysfunction in parkin null mice: effects of aging J. Neurosci. 28 2008 598 611 18199761 PMC6670347
  59. [70]Solano R.M. Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxide-induced toxicity Neuropharmacology 51 2006 327 340 16701721
  60. [71]Schmidt S. Genetic mouse models for Parkinson’s disease display severe pathology in glial cell mitochondria Hum. Mol. Genet. 20 2011 1197 1211 21212098
  61. [72]Ledesma M.D. Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stress J. Neurochem. 83 2002 1431 1440 12472897
  62. [73]Khasnavis S. Pahan K. Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson’s disease J. Neuroimmune Pharmacol. 9 2014 569 581 24946862 PMC4167597
  63. [74]Kim B. Impaired inflammatory responses in murine Lrrk2–knockdown brain microglia PLoS One 7 2012 e34693 22496842 PMC3322140
  64. [75]Moehle M.S. LRRK2 inhibition attenuates microglial inflammatory responses J. Neurosci. 32 2012 1602 1611 22302802 PMC3532034
  65. [76]Pike L.J. Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis Biochemistry 41 2002 2075 2088 11827555
  66. [77]Alkayed N.J. Inhibition of brain P-450 arachidonic acid epoxygenase decreases baseline cerebral blood flow Am. J. Physiol. 271 1996 H1541 H1546 8897950
  67. [78]Blanco V.M. Tone-dependent vascular responses to astrocyte-derived signals Am. J. Physiol. Heart Circ. Physiol. 294 2008 H2855 H2863 18456724 PMC3962545
  68. [79]Sergeeva M. Arachidonic acid in astrocytes blocks Ca(2+) oscillations by inhibiting store-operated Ca(2+) entry, and causes delayed Ca(2+) influx Cell Calcium 33 2003 283 292 12618149
  69. [80]Grabner G.F. Deletion of monoglyceride lipase in astrocytes attenuates lipopolysaccharide-induced neuroinflammation J. Biol. Chem. 291 2016 913 923 26565024 PMC4705409
  70. [81]Tofaris G.K. Lysosome-dependent pathways as a unifying theme in Parkinson’s disease Mov. Disord. 27 2012 1364 1369 22927213
  71. [82]Bose A. Beal M.F. Mitochondrial dysfunction in Parkinson’s disease J. Neurochem. 139 Suppl. 1 2016 216 231 27546335
  72. [83]Lopez-Armada M.J. Mitochondrial activity is modulated by TNFalpha and IL-1beta in normal human chondrocyte cells Osteoarthr. Cartil. 14 2006 1011 1022 16679036
  73. [85]Tyzack G. Human stem cell-derived astrocytes: specification and relevance for neurological disorders Curr. Stem Cell Rep. 2 2016 236 247 27547709 PMC4972864
  74. [86]Tawfik V.L. Deep brain stimulation results in local glutamate and adenosine release: investigation into the role of astrocytes Neurosurgery 67 2010 367 375 20644423 PMC2919357
  75. [87]Patel N.K. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study Ann. Neurol. 57 2005 298 302 15668979
  76. [88]Slevin J.T. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal J. Neurosurg. 106 2007 614 620 17432712
  77. [89]Lang A.E. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease Ann. Neurol. 59 2006 459 466 16429411
  78. [90]Nutt J.G. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 60 2003 69 73 12525720
  79. [91]Barker R.A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease Lancet Neurol. 12 2013 84 91 23237903
  80. [92]Grealish S. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson’s disease Cell Stem Cell 15 2014 653 665 25517469 PMC4232736
  81. [93]Gagne J.J. Power M.C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis Neurology 74 2010 995 1002 20308684 PMC2848103
  82. [94]Aflaki E. A new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism J. Neurosci. 36 2016 7441 7452 27413154 PMC4945664
  83. [96]Bakshi R. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release Neurobiol. Dis. 82 2015 574 579 26341543 PMC4641017
  84. [97]Ahuja M. Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced experimental Parkinson’s-Like disease J. Neurosci. 36 2016 6332 6351 27277809 PMC4899530
  85. [98]Schober A.L. Recombinant adeno-associated virus serotype 6 (rAAV6) potently and preferentially transduces rat astrocytes in vitro and in vivo Front. Cell. Neurosci. 10 2016 262 27891076 PMC5104754

Cited by

Sorted by citations

Authors
Booth, H. D. E., Hirst, W. D., & Wade-Martins, R.
Affiliations
  • University of Oxford (GB)
  • Biogen (United States) (US)
ORCID
Venue
Trends in Neurosciences
Publisher
Elsevier BV
Published
2017-06
Volume
40
Issue
6
Pages
358-370
ISSN
0166-2236 (ISSN-L)
DOI
10.1016/j.tins.2017.04.001
PMC
PMC5462417
OpenAlex
W2616733389
Cited by
633
References
13
Citations by year
2026: 49 · 2025: 85 · 2024: 73 · 2023: 76 · 2022: 94 · 2021: 81 · 2020: 79 · 2019: 60 · 2018: 31 · 2017: 5
FWCI
6.42
Type
journal article
Language
en
Open access
Licence
Locations
  • Trends in Neurosciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion, cc-by)
Funders
  • Parkinson's UK (J-1403, J-0901)
  • Medical Research Council (MR/L023784/1, MR/M024962/1, MC_EX_MR/N50192X/1)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
Keywords
astrocytes, Parkinson's disease, astrocyte dysfunction, neurodegeneration, pathogenesis, glial cells, disease-associated genes, astrocyte function, Parkinson's disease treatment
MeSH terms
Animals, Astrocytes, Humans, Parkinson Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review